@article { author = {Gholami Parizad, Elaheh and Imani Fooladi, Abbas Ali and Sedighian, Hamid and Behzadi, Elham and valizadeh, Azar and Khosravi, Afra}, title = {Comparison of Immune Response in Mice Immunized with Recombinant PreS2/S-C18-27 Protein Derived from Hepatitis B Virus with Commercial Vaccine}, journal = {Iranian Journal of Pathology}, volume = {17}, number = {4}, pages = {448-460}, year = {2022}, publisher = {Farname Inc in collaboration with Iranian Society of Pathology}, issn = {1735-5303}, eissn = {2345-3656}, doi = {10.30699/ijp.2022.553785.2896}, abstract = {Background & Objective: The vaccine available to prevent Hepatitis B virus disease is ineffective in 5% of people due to the use of HBsAg as a weak immunogen. In the present study, PreS2/S fused to C18-27 peptide fragment as an effective antigen and is proposed as a promising vaccine candidate compared with the conventional vaccine prescribed in the vaccination program.Methods: After the synthesis of PreS2/S genes and C18-27 peptide fragment in pET28a, the recombinant protein was confirmed by Western blotting. The efficacy of the PreS2/S-C18-27 protein was compared with the conventional vaccine injected into five groups of rats. Finally, the cytokine level of IF-r, IL-2, IL-4, IL-10, TNF-a, IgG1, and IgG2a were measured using the ELISA method.Results: This study showed no significant difference between the recombinant vaccine group and PBS control group in the IF-r test, but there was a significant difference between groups testing IL-2 and IL-10. In addition, the group receiving the recombinant vaccine with CPG adjuvant at a dilution of 1/10 in the IgG total test on days 14 and 45 after the first injection showed a significant difference in comparison with other groups.Conclusion: This study showed no statistically significant difference between the recombinant protein vaccine group and the conventional vaccine group. The Th1- mediated immune responses obtained from recombinant proteins with and without CPG performed better than conventional vaccines, possibly due to the functional deficiency of the available vaccines.}, keywords = {CpG 7909,Hepatitis B Core Antigen,Hepatitis B Vaccines,Hepatitis B virus,preS2HBsAg}, url = {https://ijp.iranpath.org/article_254533.html}, eprint = {https://ijp.iranpath.org/article_254533_15cd5c6d53a51c9ad6c852bd0ea36c88.pdf} }